Relief Therapeutics Hldg (OP:RLFTF)

0.2655 UNCHANGED

Last Price Updated: 2:52 PM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Relief Therapeutics Hldg

Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate ↗

November 14, 2022

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate ↗

June 21, 2022

Via Benzinga

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗

June 05, 2022

Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights ↗

January 13, 2022

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing...

Via Benzinga

NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today ↗

January 05, 2022

News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing.

Via InvestorPlace

BYND Stock: 11 Things for Plant-Based Investors to Know About the KFC Beyond Meat ‘Fried Chicken’ News ↗

January 05, 2022

Beyond Meat (BYND) stock is on the move today as investors react to news of Yum Brand's (YUM) KFC adopting plant-based fried chicken.

Via InvestorPlace

RLFTF Stock Alert: What Is Going on With Relief Therapeutics Today? ↗

January 05, 2022

RLFTF stock and NRXP stock are both gaining this morning after NRx Pharmaceuticals filed for emergency use for its Covid-19 treatment.

Via InvestorPlace

Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday ↗

December 14, 2021

Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate ↗

November 24, 2021

Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied...

Via Benzinga

NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful ↗

November 05, 2021

The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing...

Via Benzinga

Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment ↗

October 27, 2021

Relief Therapeutics Holding SA's (OTC: RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of...

Via Benzinga

Why NRx Pharmaceuticals Stock Is Tumbling Today ↗

October 15, 2021

The drugmaker is being sued by Relief Therapeutics.

Via The Motley Fool

Topics Lawsuit

Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review ↗

October 06, 2021

The FDA has accepted for review Acer Therapeutics Inc (NASDAQ: ACER) and its partner, Relief Therapeutics Holding SA's (OTC: RLFTF) marketing...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis ↗

August 03, 2021

The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's (OTC: RLFTF) for RLF-100 (aviptadil), an inhaled formulation, for...

Via Benzinga

Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday? ↗

July 23, 2021

Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday. NRx's stock opened Thursday...

Via Benzinga

NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure ↗

June 01, 2021

NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19...

Via Benzinga

Review Of Present Therapies For Covid-19 ↗

May 09, 2021

A summary of authorized drugs for Covid-19, those in development, and those that have failed.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.